The Endpoint

DaVita executives said that the dialysis provider would not participate in CMS' new renal ACO demo unless the agency makes changes to some of its rules.

Small storms can turn into big disasters

Once oral dialysis drugs like Amgen's Sensipar, used to treat hyperparathyroidism, are included in the dialysis payment bundle, it is unlikely that the inevitable drop in sales will match what the biotech firm has seen from its anemia drugs.

A highlight of some of the biggest research stories posted on NephrologyNews.com in 2012.

Dialysis providers might have to justify their payment rate.

This new bi-weekly summary is intended to highlight the important stories from and about the kidney care community and offer a place to analyze and discuss them, as well as dive deeper into some of the issues we are covering on our website and in the pages of our magazine.

We reviewed submitted comments to CMS, which were due to the agency by Aug. 31, from a number of patient and professional organizations.

Despite overwhelming evidence that extending coverage would save lives, donated kidneys, and money, policymakers remain, according to a new perspective piece in The New England Journal of Medicine, penny wise and pound foolish.

Was Rep. Shelley Berkley's push to save a transplant center unethical?